IN 1946 we presented a description and explanation of a set of cards used by the Rochester Child Health Project in its well baby clinics. These cards, it was hoped, would help the attending physicians to learn about and to record the evidences of growth and development of babies as they appear in the first twelve months of life. In this article we shall describe and explain a similar set of cards devised for use in the second year. After the first year, growth and development are not so rapid as they are earlier; the changes from month to month are not so evident and methods of managing a child need not be altered so frequently. Therefore the mothers are asked to bring children in for conferences at fourteen, sixteen, eighteen, twenty-one and twenty-four months of age only. Thus, only five cards are needed in the second year. The following material appears on the respective cards. Information given under the numbered headings appears on the faces of the cards; the explanatory notes are printed on the reverse. CARD 1. SUBJECTS TO BE CONSIDERED AT THE AGE OF FOURTEEN MONTHS 1. Development : Baby walks; may even be able to run and climb. Pushes, pulls and piles large objects. May turn pages of a book one at a time. 2. Habits: Eating—Baby may have full adult diet, except for nuts, berries, fat meats and highly seasoned foods. May continue to have bedtime bottle if he desires it. Self-feeding with fingers, spoon, cup or glass should be encouraged even if result is messy. Sleeping—Baby's night sleep may be disturbed. May take one or two naps, tending toward one. Elimination—Bowel: Baby may indicate time for bowel movement. Bladder: Mother may "catch" urine in toilet; if not successful, she should stop trying for two or three weeks; progress should not be forced. Mother understands meaning of "catching" from explanation given her concerning bowel control when child was in sixth month of life. 3. Social adjustment: Baby is becoming increasingly independent; wants to help undress and feed himself; objects to play pen. Enjoys the rhythm of singing, of the radio and of being read to. Speech—Baby can say a word or two, especially if composed of repeated syllables (mama, byebye). 4. Physical examination: Examiner records anything noteworthy.
National Kidney Foundation Laboratory Engagement Working Group Recommendations for Implementing the CKD-EPI 2021 Race-Free Equations for Estimated Glomerular Filtration Rate: Practical Guidance for Clinical Laboratories
Abstract Recognizing that race is a social and not a biological construct, healthcare professionals and the public have called for removal of race in clinical algorithms. In response, the National Kidney Foundation and the American Society of Nephrology created the Task Force on Reassessing the Inclusion of Race in Diagnosing Kidney Diseases to examine the issue and provide recommendations. The final report from the Task Force recommends calculating estimated glomerular filtration rate (eGFR) without a race coefficient using the recently published CKD-EPI 2021 creatinine (cr) and creatinine-cystatin C (cr-cys) equations. The Task Force recommends immediately replacing older eGFRcr equations (MDRD Study and CKD-EPI 2009) with the new CKD-EPI 2021 equation. In a 2019 survey by the College of American Pathologists, 23% of 6200 laboratories reporting eGFRcr used an incorrect equation that is not suitable for use with standardized creatinine measurements, 34% used the CKD-EPI 2009 equation and 43% used the MDRD Study 2006 equation re-expressed for standardized creatinine measurement. Rapid transition to using the CKD-EPI 2021 equation is an opportunity for laboratories to standardize to a single equation to eliminate differences in eGFRcr due to different equations used by different laboratories, and to report eGFR without use of race. We provide guidance to laboratories for implementing the CKD-EPI 2021 equations for both eGFRcr and eGFRcr-cys.
Metabolic Aspects of Myocardial Disease and a Role forl-Carnitine in the Treatment of Childhood Cardiomyopathy
Objectives.A multicenter retrospective study was conducted to investigate the possible metabolic causes of pediatric cardiomyopathy and evaluate the outcome of patients treated with l-carnitine.Methods.Seventy-six patients diagnosed with cardiomyopathy were treated with l-carnitine in addition to conventional cardiac treatment, and 145 patients were treated with conventional treatment only. There were 101 males and 120 females between 1 day and 18 years old. Cardiomyopathy diagnoses included dilated (148 patients), hypertrophic (42 patients), restrictive (16 patients), mixed diagnosis (11 patients), and 4 with an unknown type. Of 76 l-carnitine-treated patients, 29 (38%) had evidence to suggest a disorder of metabolism, and of 145 control patients, 15 (10%) were suspected to have a disorder of metabolism. These metabolic disorders were thought to be the cause for the cardiomyopathy of the patients. The duration of l-carnitine treatment ranged from 2 weeks to >1 year. Information was collected on length of survival (time-to-event), clinical outcome, echocardiogram parameters, and clinical assessments. Data were collected at intervals from baseline to study endpoint, death, transplant, or last known follow-up visit.Results.l-Carnitine-treated patients were younger than control patients and had poorer clinical functioning at baseline, yet they demonstrated lower mortality and a level of clinical functioning and clinical severity comparable to control patients on conventional therapy by the end of the study. An analysis of the interaction between clinical outcome and concomitant medications unexpectedly revealed that the population of patients treated with angiotensin-converting enzyme (ACE) inhibitors (40% of patients) had significantly poorer survival (although their greater likelihood for poor survival may possibly have made them more likely to receive ACE inhibitors).Conclusion.Results suggest that l-carnitine provides clinical benefit in treating pediatric cardiomyopathy. There is a need for further exploration of potential explanatory factors for the higher mortality observed in the population of patients treated with ACE inhibitors.
VITAMIN D DEPENDENCY: AN INHERITED POSTNATAL SYNDROME WITH SECONDARY HYPERPARATHYROIDISM
Three French-Canadian children in a large inbred pedigree each developed hypocalcemic, hypophosphatemic rickets in the latter half of their first year of life; there were also manifestations of generalized renal tubular dysfunction. These abnormalities, which mimic advanced Vitamin D deficiency, disappeared only when Vitamin D2 or D3 was given at about 100 times the recommended daily allowance; this indicated the diagnosis of Vitamin D dependency. Enamel hypoplasia was a prominent clinical finding; only those teeth which calcify postnatally were affected, indicating that the condition found does not affect Vitamin D-dependent nutrition in utero. The level of parathyroid hormone was elevated in serum before treatment; it fell to normal either after treatment with Vitamin D, or during intravenous infusion with a calcium solution sufficient to produce hypercalcemia. Vitamin D dependency appeared to be inherited as an autosomal recessive trait in this pedigree, but we could observe no phenotypic signs in presumably obligate heterozygotes. One of the three cases in the pedigree arose from outbreeding, suggesting that the mutant allele is probably not particularly rare in the population under our surveillance.
A Pill for Sexual Desire in Female Cancer Survivors: Too Good to Be True?
An infant with Hodgkin's disease and thymic alymphoplasia is described. The infant died at 5 months of age after an illness clinically characterized by frequent respiratory infections, erythematous rash, oral thrush, and hepatosplenomegaly. The peripheral blood showed severe anemia and lymphopenia; IgG level was very low, and there was no mitosis of peripheral lymphocytes after stimulation with phytohemagglutinin. Autopsy revealed Pneumocystis carinii pneumonia, thymic alymphoplasia, and Hodgkin's lymphoma in lymph nodes, liver, spleen, and lungs. A reovirus type 3 was isolated from the lungs. The association of diseases as rare as Hodgkin's disease and thymic alymphoplasia suggests a relationship between them. This may consist of either an abnormal susceptibility to oncogenic virus or an inability to destroy mutant cells in an infant with congenital immunologic-deficiency syndrome.
SUDDEN, UNEXPECTED, AND UNEXPLAINED DEATH IN INFANTS
Among 210 deaths in infants aged 2 weeks to 2 years in Olmsted County, Minnesota, during the 20-year period 1946 through 1965, review of the clinical and pathologic reports disclosed 37 instances of sudden, unexpected, unexplained death (SUUD). The incidence rate was 1.2/1,000 live births. The death occurred between midnight and noon in 90% of cases, and all but one of the children were found dead in bed. Some seasonal variation was noted. Autopsy was done in 75% of the 210 instances, including 86% (32) of the SUUD cases. More than two thirds of the cases of SUUD coming to autopsy had some evidence of an infectious disease, but these findings were minimal and in no case sufficient in themselves to cause death. Therefore, it was concluded that a second factor is necessary to initiate the sequence of events that leads to death, although the specific trigger mechanisms are unknown and may be quite variable.
Development and evaluation of IL‐6 overexpressing mesenchymal stem cells (MSCs)
AbstractIntroductionThis study presents a comprehensive collision avoidance framework based on three‐dimension (3D) computer‐aided design (CAD) modeling, a graphical user interface (GUI) as peripheral to the radiation treatment planning (RTP) environment, and patient‐specific plan parameters for intensity‐modulated proton therapy (IMPT).MethodsA stand‐alone software application was developed leveraging the Varian scripting application programming interface (API) for RTP database object accessibility. The Collision Avoider software models the Hitachi ProBeat‐V half gantry design and the Kuka robotic couch with triangle mesh structures. Patient‐specific plan parameters are displayed in the collision avoidance software for potential proximity evaluation. The external surfaces of the patients and the immobilization devices are contoured based on computed tomography (CT) images. A “table junction‐to‐CT‐origin” (JCT) measurement is made for every patient at the time of CT simulation to accurately provide reference location of the patient contours to the treatment couch. Collision evaluations were performed virtually with the program during treatment planning to prevent four major types of collisional events: collisions between the gantry head and the treatment couch, gantry head and the patient's body, gantry head and the robotic arm, and collisions between the gantry head and the immobilization devices.ResultsThe Collision Avoider software was able to accurately model the proton treatment delivery system and the robotic couch position. Commonly employed clinical beam configuration and JCT values were investigated. Brain and head and neck patients require more complex gantry and patient positioning system configurations. Physical measurements were performed to validate 3D CAD model geometry. Twelve clinical proton treatment plans were used to validate the accuracy of the software. The software can predict all four types of collisional events in our clinic since its full implementation in 2020.ConclusionA highly efficient patient‐specific collision prevention program for scanning proton therapy has been successfully implemented. The graphical program has provided accurate collision detection since its inception at our institution.